Generex Biotechnology Corp. (fka GNBTQ)

[spaceblob]

GALE worth $50 potentially with NeuVax approval:

Phase IIb and III trials will determine whether GALE goes to $50 or possibly 50 cents

OK, $50 is a stretch, but not outside the realm of possibility in the biotech/pharmaceutical sector.

http://wallstcheatsheet.com/business/stock-news/heres-why-galena-pharmaceuticals-neuvax-is-the-real-deal.html/?a=viewall

Ae37 potentially superior to NeuVax. Here are comments from lead Antigen Express researcher re: NeuVax vs. Antigen:

"Most other peptide vaccines out there, including Galena's, are HLA restricted, so the oncologists would have to do an extra diagnostic test that cancer patients normally do not need to see if they have the particular allele that would allow them to be eligible for that vaccine. AE37 interacts with lots of different alleles, so in fact it's impossible to find someone without an allele that interacts with AE37. An oncologist doesn't need to have a patient be subject to any additional tests to determine if that patient is eligible for AE37. And you're correct, we are also treating the high risk node negative, so we expand that beyond the node positive. We essentially double the market of what other peptide vaccines can do, such as NeuVax, which are restricted to 50% of the market. We target twice the market."

From Seeking Alpha:

"With important catalyst on the horizon, GNBT is a stock to watch. The company's market cap has miles and miles to grow before being anywhere near close to its main oncology rival."

GLTA.